TP53 and breast cancer: Compared with vehicle + topotecan, Ko143+ topotecan combination therapy significantly (P = 0.022, Log-rank test) increased overall survival of the Abcg2−/− animals that carried Brca1−/−;p53−/− mammary tumors (Fig. 1B).